<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429988</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000378088</org_study_id>
    <secondary_id>UCSF-TEMP01</secondary_id>
    <nct_id>NCT00429988</nct_id>
  </id_info>
  <brief_title>Study of Ductal Lavage in Women at High Risk for Breast Cancer</brief_title>
  <official_title>Ductal Lavage to Monitor and Treat High Risk Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting samples of fluid using ductal lavage and nipple aspiration from&#xD;
      participants at high risk for breast cancer to study in the laboratory may help doctors learn&#xD;
      more about changes that may occur in DNA and identify biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This clinical trial is using ductal lavage to collect fluid from women at high risk&#xD;
      for breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the volume of atypical cells collected from ductal lavage in women at&#xD;
           increased risk for breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine assay techniques to analyze nipple aspirate fluid and ductal lavage fluid&#xD;
           samples from these participants.&#xD;
&#xD;
        -  Analyze the nipple aspirate fluid from these participants for specific and global&#xD;
           protein signatures.&#xD;
&#xD;
        -  Determine the replicability of markers in serial assays of these participants.&#xD;
&#xD;
        -  Determine the percentage of participants with atypia on ductal lavage in which ductal&#xD;
           lesions can be identified using ductoscopy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Participants undergo nipple aspirate fluid and ductal lavage fluid collection. Fluid samples&#xD;
      are analyzed using cytological analysis, immunohistochemistry, fluorescent in situ&#xD;
      hybridization, or in situ polymerase chain reaction. Protein patterns are identified using&#xD;
      mass spectrometry.&#xD;
&#xD;
      Participants found to have atypia undergo repeat lavage at 3-6 months and 1 year.&#xD;
      Participants with normal fluid samples undergo repeat lavage at 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 participants will accrued for this study within 2-3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Average number of atypical cells per ductal lavage sample</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assay techniques development for nipple aspirate fluid and ductal lavage fluid analysis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific and global protein signature analysis of nipple aspirate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Replicability of markers in serial assays</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with atypia on ductal lavage in which ductal lesions can be identified using ductoscopy</measure>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cytology specimen collection procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>breast duct lavage</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women at increased risk for breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  High risk for breast cancer defined as 1 of the following:&#xD;
&#xD;
               -  History of atypical hyperplasia or atypia found on biopsy, fine-needle&#xD;
                  aspiration, or ductal lavage&#xD;
&#xD;
               -  Family history of cancer meeting at least 1 of the following criteria:&#xD;
&#xD;
                    -  Single relative with multiple primary cancers&#xD;
&#xD;
                    -  One or more relative under 40 years of age with breast cancer OR bilateral&#xD;
                       breast cancer&#xD;
&#xD;
                    -  Two or more relatives with ovarian cancer&#xD;
&#xD;
                    -  Two or more relatives with breast cancer and 1 is under 50 years of age&#xD;
&#xD;
                    -  One or more relative with breast cancer plus â‰¥ 1 relative with ovarian&#xD;
                       cancer&#xD;
&#xD;
                    -  Ashkenazi Jewish descent AND relative with breast cancer under 50 years of&#xD;
                       age OR ovarian cancer at any age&#xD;
&#xD;
               -  BRCA1 and/or BRCA2 mutation&#xD;
&#xD;
               -  Prior breast cancer in contralateral breast&#xD;
&#xD;
               -  Gail risk &gt; 1.7%&#xD;
&#xD;
               -  Spontaneous nipple discharge&#xD;
&#xD;
               -  Serum estradiol &gt; 10 pmol/L&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Able to obtain breast duct fluids&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 months since prior tamoxifen or raloxifene&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the breast&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior incisional or excisional biopsy within 1.5 cm of nipple&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior neoadjuvant therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura J. Esserman, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

